Based on these promising preclinical data, an early phase clinical trial was opened to explore the CD37 CAR-T cells for CD37+ hematologic malignancies, including mature B cell neoplasms, mature T cell neoplasms, and T-cell or B-cell prolymphocytic leukemia (NCT04136275). This evidence concerns the gene CD37 and hematologic disorder.